Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | FAAH | O00519 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.63 |
| ▸ | PAFAH1B2 | P68402 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | MGLL | Q99685 | 1/20 | 0.63 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.63 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.51 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL458863 | 1.00 | MEN1 (0.63) | MEN1FAAHALDH1A1MAPTPLA2G4A | |
| SCHEMBL1887711 | 0.98 | MEN1 (0.61) | MEN1FAAHALDH1A1MAPTPLA2G4A | |
| SCHEMBL2783833 | 0.92 | MEN1 (0.59) | MEN1FAAHALDH1A1MAPTPLA2G4A | |
| SCHEMBL4138344 | 0.89 | LPAR3 (0.58) | MEN1FAAHALDH1A1MAPTPLA2G4A | |
| SCHEMBL177497 | 0.88 | MEN1 (0.56) | MEN1FAAHALDH1A1MAPTPLA2G4A | |
| SCHEMBL19877181 | 0.88 | MEN1 (0.56) | MEN1FAAHALDH1A1MAPTPLA2G4A | |
| SCHEMBL22187633 | 0.85 | ALDH1A1 (0.59) | MEN1FAAHALDH1A1MAPTPLA2G4A | |
| SCHEMBL22187634 | 0.85 | ALDH1A1 (0.59) | MEN1FAAHALDH1A1MAPTPLA2G4A | |
| SCHEMBL30309871 | 0.83 | LPAR3 (0.55) | MEN1FAAHALDH1A1MAPTPLA2G4A | |
| SCHEMBL2783835 | 0.83 | LPAR3 (0.63) | MEN1FAAHALDH1A1MAPTPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 568 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119647032-A | Emergency material transportation network design method | 兰州交通大学 | 2025-03-18 | — | — | CN | claimed |
| WO-2024163538-A2 | MODULATION OF LYSOSOMAL PHOSPHOLIPASE A2 FOR TREATMENT OF BIS (MONOACYLGLYCERO)PHOSPHATE-RELATED DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-08-08 | — | — | WO | claimed |
| EP-4401570-A1 | NON-ANIMAL BASED PROTEIN SOURCES WITH FUNCTIONAL PROPERTIES | Clara Foods Co. (US) | 2024-07-24 | — | — | EP | claimed |
| WO-2024073476-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER BY REDUCING THE EXPRESSION AND/OR ACTIVITY OF PLA2G10 | YALE UNIVERSITY (US) | 2024-04-04 | — | — | WO | claimed |
| CN-117392006-A | Novel DU-Net model-based image defogging method | 中国石油大学(华东) | 2024-01-12 | — | — | CN | claimed |
| WO-2023044396-A1 | NON-ANIMAL BASED PROTEIN SOURCES WITH FUNCTIONAL PROPERTIES | CLARA FOODS CO. (US) | 2023-03-23 | — | — | WO | claimed |
| US-20230060937-A1 | SIMULTANEOUS GENE EDITING AND HAPLOID INDUCTION | SYNGENTA PARTICIPATIONS AG (CH) | 2023-03-02 | — | — | US | claimed |
| EP-3899016-A1 | SIMULTANEOUS GENE EDITING AND HAPLOID INDUCTION | Syngenta Participations AG (CH) | 2021-10-27 | — | — | EP | claimed |
| EP-3677259-A1 | USE OF ARACHIDONYL TRIFLUOROMETHYL KETONE | Mosaiques Diagnostics And Therapeutics AG (DE) | 2020-07-08 | — | — | EP | claimed |
| WO-2020131788-A1 | SIMULTANEOUS GENE EDITING AND HAPLOID INDUCTION | SYNGENTA PARTICIPATIONS AG (CH) | 2020-06-25 | — | — | WO | claimed |
| WO-2007022427-A2 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | ACCELALOX, INC. (US) | 2007-02-22 | — | — | WO | claimed |
| US-20060058225-A1 | Used of inhibitors of phospholipase a2 for the treatment, prevention or diagnosis of neural inflammatory or demyelinating disease | MCGILL UNIVERSITY | 2006-03-16 | — | — | US | claimed |
| EP-1509247-A1 | USE OF INHIBITORS OF PHOSPHOLIPASE A2 FOR THE TREATMENT, PREVENTION OR DIAGNOSIS OF NEURAL INFLAMMATORY OR DEMYELINATING DIESEASES | McGILL UNIVERSITY (CA) | 2005-03-02 | — | — | EP | claimed |
| US-20040127572-A1 | Functional role for cannabinoids in autonomic stability during sleep | CARLEY DAVID W (US) | 2004-07-01 | — | — | US | claimed |
| EP-1372638-A1 | FUNCTIONAL ROLE FOR CANNABINOIDS IN AUTONOMIC STABILITY DURING SLEEP | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2004-01-02 | — | — | EP | claimed |
| WO-2003101487-A1 | USE OF INHIBITORS OF PHOSPHOLIPASE A2 FOR THE TREATMENT, PREVENTION OR DIAGNOSIS OF NEURAL INFLAMMATORY OR DEMYELINATING DISEASE | MCGILL UNIVERSITY (CA) | 2003-12-11 | — | — | WO | claimed |
| US-20030225011-A1 | Phospholipase A2 expression and activity and use thereof for diagnosis, prognostication, prevention and treatment of neural inflammatory and demyelinating disease | MCGILL UNIVERSITY (CA) | 2003-12-04 | — | — | US | claimed |
| WO-2002080903-A1 | FUNCTIONAL ROLE FOR CANNABINOIDS IN AUTONOMIC STABILITY DURING SLEEP | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2002-10-17 | — | — | WO | claimed |
| WO-2001055166-A1 | CLONED HUMAN LYSOPHOSPHOLIPASE | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-08-02 | — | — | WO | claimed |
| WO-2000002561-A1 | MODULATION OF THE PHOSPHOLIPASE A2 PATHWAY AS A THERAPEUTIC | UNIVERSITY OF SOUTH FLORIDA (US) | 2000-01-20 | — | — | WO | claimed |